Senate Republicans to challenge auto safety mandates in January - WSJ
Investing.com - BTIG has reiterated its Neutral rating on Vericel Corporation (NASDAQ:VCEL) following a meeting with company management during a Boston area bus tour on Wednesday. The stock currently trades at $38.95, approximately 38% below its 52-week high of $63.
The research firm noted that Vericel recently delivered stronger-than-expected third-quarter results, with revenue growth driven by a combination of MACI, Epicel, and NexoBrid all performing better than anticipated, while MACI Arthro remains in the early launch phase. InvestingPro data shows Vericel achieved 14.05% revenue growth in the last twelve months, with total revenue reaching $258.72 million.
BTIG’s discussions with Vericel management primarily focused on MACI Arthro dynamics, which represents the company’s major growth driver into 2026. The firm had previously downgraded Vericel shares in September based on softer survey results relative to Street estimates for fiscal year 2026 and beyond.
Since BTIG’s September downgrade, MACI’s fiscal year 2026 growth projections have been reduced and now sit at approximately 19.1% year-over-year growth.
Despite Vericel seeing positive early indicators in the MACI Arthro launch, BTIG maintains its Neutral stance, believing upside remains limited relative to current Street estimates.
In other recent news, Vericel Corporation reported impressive third-quarter 2025 earnings, surpassing expectations. The company achieved an earnings per share (EPS) of $0.10, significantly outperforming the projected -$0.01. Revenue also exceeded forecasts, reaching $67.5 million compared to the anticipated $64.56 million. These results highlight Vericel’s strong financial performance during this period. While the earnings report was a major highlight, there were no recent updates regarding mergers or acquisitions. Analyst reactions to these results have not been specified in recent reports. Other company developments have not been detailed in the latest news.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.